News Releases

Webcast Image Webcast
Jaguar Health Earnings Conference Call
Nov 14, 2017 at 5:45 PM EST
Date Title  
Toggle Summary Experts Highlight that Immune System Activation in Aging Patients Living with HIV/AIDS Triggers Effects Such as "Leaky Gut", Which Can Lead to Diarrhea
Mytesi for HIV-related Diarrhea Now on ADAP Formularies in 22 States SAN FRANCISCO, CA / ACCESSWIRE / April 19, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived
Toggle Summary Jaguar Subsidiary Napo Pharmaceuticals Signs Agreement with the ADAP Crisis Task Force for Mytesi
Agreement Provides Pricing for Mytesi to Each U.S. State's AIDS Drug Assistance Program (ADAP) - Organizations that Provide HIV-related Services and Approved Medications to More than Half a Million People Annually SAN FRANCISCO, CA / ACCESSWIRE / April 10, 2018 /  Jaguar Health, Inc.
Toggle Summary Recent Publications Indicate that Diarrhea is a Significant and Serious Issue in HIV
Article in the Journal AIDS Care Shows That Patients with Diarrhea Have Poor Adherence to Their Antiretroviral Therapy (ARV) Regimen SAN FRANCISCO, CA / ACCESSWIRE / April 9, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal
Toggle Summary Jaguar Health Appoints Jonathan B. Siegel to Board of Directors
SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that it has
Toggle Summary Jaguar Health Announces Up to $16.2 Million in Equity Financings in Separate Private Placement Investments, Including Investment by Sagard Capital Partners, L.P., to Continue Commercialization of FDA-Approved Mytesi
Largest Investor Locked in for 12 Months SAN FRANCISCO, CA / ACCESSWIRE / March 26, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a
Toggle Summary FDA Indicates that Jaguar's Reasonable Expectation of Effectiveness Technical Section is Complete for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs
SAN FRANCISCO, CA / ACCESSWIRE / March 8, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the U.S.
Toggle Summary Jaguar Health Subsidiary, Napo Pharmaceuticals, Signs Agreement with Pharmacy Services Provider "Transition Patient Services" to Establish Nationwide Pilot "Mytesi Direct" Program
Toggle Summary Jaguar Health Provides Updates Regarding Commercial, Educational & Product Development Programs and 2017 Results for Mytesi Since Merger (August–December 2017)
Mytesi Sales Increased 17.71% Each Month Over the Prior Month SAN FRANCISCO --(BUSINESS WIRE)--Jan. 22, 2018-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal
Toggle Summary Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 Results
SAN FRANCISCO --(BUSINESS WIRE)--Jan. 18, 2018-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global
Toggle Summary Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde Krim
SAN FRANCISCO --(BUSINESS WIRE)--Jan. 18, 2018-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc.
Toggle Summary Jaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguar’s Personalized, Premium Product for Total Gut Health and Wellness in Horses
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 14, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis,
Toggle Summary New Survey Finds People Living With HIV With Diarrhea Often Suffer in Silence
A change in the way doctors and patients talk about symptoms could better address this neglected comorbidity in HIV SAN FRANCISCO --(BUSINESS WIRE)--Dec. 12, 2017-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products
Toggle Summary Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 1, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global
Toggle Summary Keep Your Pants On Campaign From Napo Pharmaceuticals Chosen as Best HIV-Related Awareness Campaign of 2017 by Healthline
Campaign designed to raise awareness of the issue of diarrhea among people with HIV/AIDS and encourage them to speak with their healthcare providers SAN FRANCISCO --(BUSINESS WIRE)--Dec. 1, 2017-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel
Toggle Summary Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLC
Registered Direct at $0.25 Per Share and Equity Line at Fixed Price of $0.52 Per Share SAN FRANCISCO --(BUSINESS WIRE)--Nov. 27, 2017-- Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably
Toggle Summary Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals
As a Result of the Merger, Jaguar Shows Positive Net Income for Q3 2017 SAN FRANCISCO --(BUSINESS WIRE)--Nov. 20, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived
Toggle Summary Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napo’s FDA-Approved Human Prescription Drug
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 15, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis,
Toggle Summary Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Health’s Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8 Million
Expansion of National Salesforce Continues for Mytesi as Napo Significantly Ramps Up Post-Merger Product Commercialization and Launch Activities in Response to Impact of Over 50% Sales Growth Since Merger SAN FRANCISCO --(BUSINESS WIRE)--Nov. 14, 2017-- Jaguar Health, Inc.
Toggle Summary Today’s Jaguar Health Conference Call Moved to 5:45 p.m. Eastern Time
First Post-Merger Earnings Call for Jaguar and its Wholly-Owned Subsidiary, Napo Pharmaceuticals , Regarding Sales of Napo’s FDA-Approved Human Drug, Mytesi, an Antidiarrheal Indicated for the Symptomatic Relief of Noninfectious Diarrhea in Adult Patients with HIV/AIDS on Antiretroviral Therapy SAN
Toggle Summary Jaguar Health to Host Earnings Conference Call Tuesday, November 14th at 4:30 p.m. Eastern Time
First Post-Merger Earnings Call for Jaguar and its Wholly-Owned Subsidiary, Napo Pharmaceuticals , Regarding Sales of Napo’s FDA-Approved Human Drug, Mytesi, an Antidiarrheal Indicated for the Symptomatic Relief of Noninfectious Diarrhea in Adult Patients with HIV/AIDS on Antiretroviral Therapy SAN
Toggle Summary Jaguar Health Enters Non-Binding Agreement of Terms to Issue a Secured Convertible Note to Iliad Research and Trading, L.P. (an Affiliate of Chicago Venture Partners, L.P.), as Jaguar Expands Commercial Efforts for Mytesi
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 8, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar"), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis,
Toggle Summary Jaguar Health Receives Approval from The American Association of Veterinary State Boards RACE Committee for Continuing Education Program for Veterinarians and Veterinary Technicians on Diarrhea in Foals
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 7, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis,
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Launches New Website for Mytesi, Napo’s FDA-Approved, First-in-Class Anti-Secretory Human Prescription Drug
Site Provides Information and Resources for Consumers as Well as HIV Physicians, Gastroenterologists and Other Healthcare Professionals SAN FRANCISCO --(BUSINESS WIRE)--Nov. 1, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Launches National “Keep Your Pants On… Unless You Don’t Want To” Campaign to Highlight the Need to Recognize and Treat Diarrhea in People Living With HIV/AIDS
Campaign Kicks Off with Events at AIDS Walk Los Angeles and Greater Palm Springs Pride as Well as Digital Ads on More Than 25 HIV/LGBT Media Outlets SAN FRANCISCO --(BUSINESS WIRE)--Oct. 26, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napo’s FDA-approved Human Prescription Drug
Leading Medical Oncologist and Hematologist Dr. Lee Schwartzberg Joins Mytesi Scientific Advisory Board for Cancer Therapy-Related Diarrhea (CTD)—An Area of Significant Concern for Diarrhea Management in the Era of Novel Targeted Agents Such as Recently Approved CDK 4/6 and Tyrosine Kinase
Toggle Summary Napo Pharmaceuticals Endorses Prevention Access Campaign’s U=U Consensus Statement for People Living With HIV/AIDS (PLWHA)
SAN FRANCISCO --(BUSINESS WIRE)--Oct. 18, 2017-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc.
Toggle Summary Jaguar Health Prices $4.25 Million Public Offering of Common Stock
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 29, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a
Toggle Summary Jaguar Subsidiary Napo Pharmaceuticals Files CMC Supplement with FDA for Sample-Size Bottles of Mytesi, Napo’s FDA-Approved Human Drug, to Support Upcoming National Sample Campaign
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 28, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably-derived gastrointestinal products for both human prescription use and veterinary use on a global
Toggle Summary Jaguar Subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals Sign Agreement Returning Key Rights in 141 Countries to Napo, Solidifying Jaguar’s Global Commercial Control of Mytesi (Crofelemer), Jaguar’s FDA-Approved Human Drug
Glenmark Will Continue to Serve as the cGMP-compliant Commercial Manufacturer of Crofelemer for Jaguar and Napo at its FDA-Approved Facilities in India Agreement Also Provides Napo with Commercial Rights to the Existing Regulatory Approvals for Crofelemer in Brazil , Ecuador , Zimbabwe & Botswana
Toggle Summary FDA Indicates That Jaguar’s Canalevia Drug Product Candidate Qualifies as “Minor Use” for Exercise-Induced Diarrhea (EID) in Dogs, Rendering Canalevia Eligible for Conditional Approval for This Indication
Jaguar Expects to Conduct the Commercial Launch of Canalevia in the First Half of 2018 for EID and CID (Chemotherapy-Induced Diarrhea) in Dogs, Dependent on Receiving Conditional Approval for These Indications SAN FRANCISCO --(BUSINESS WIRE)--Sep. 20, 2017-- Jaguar Health, Inc.
Toggle Summary Advocates Tez Anderson and Josh Robbins to Host Facebook Live Conversation on HIV/AIDS and Aging Awareness Day to Discuss Issues Affecting Long Term Survivors
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 18, 2017-- (NASDAQ: JAGX) – Today marks National HIV/AIDS and Aging Awareness Day (NHAAD), observed annually to focus on the challenges facing the aging population with regards to HIV prevention, testing, care and treatment.
Toggle Summary Jaguar Health Announces Proposed Public Offering of Common Stock
Maxim Group and Jaguar to Host Web Presentation Wednesday, September 20 th at 2 p.m. Eastern Time SAN FRANCISCO --(BUSINESS WIRE)--Sep. 18, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a natural-products pharmaceuticals company focused on developing and commercializing
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce With Hire of Experienced HIV & GI Drug Sales Reps in Key U.S. Markets
New Reps Will Target Physicians and Gastroenterologists Who Treat Large Numbers of HIV Patients SAN FRANCISCO --(BUSINESS WIRE)--Sep. 15, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably
Toggle Summary New Survey Ranks Diarrhea as Number One Gastrointestinal Complaint of HIV/AIDS Patients
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 12, 2017-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc.
Toggle Summary Jaguar Health Company Name Now Updated on Nasdaq.com Post-Merger
Jaguar’s Post-Merger Market Cap Expected to be Updated on Nasdaq.com and Other Web-based Financial Data Platforms Later this Month SAN FRANCISCO --(BUSINESS WIRE)--Aug. 16, 2017-- Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Receives Orphan-Drug Designation for Mytesi (crofelemer) for Treatment of Short Bowel Syndrome
Napo Appoints Veteran Pharmaceutical Sales Leader to Head National Sales SAN FRANCISCO --(BUSINESS WIRE)--Aug. 7, 2017-- Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal
Toggle Summary The Merger of Jaguar Animal Health and Napo Pharmaceuticals is Effective
The Combined Company’s New Name is Jaguar Health, Inc. Nasdaq Ticker Remains the Same: JAGX Merger Terms Include Additional Funding for Combined Company at $0.925/share as Disclosed in the Proxy/Prospectus SAN FRANCISCO--( BUSINESS WIRE )--The merger of Jaguar Animal Health, Inc.
Toggle Summary Stockholders of Jaguar Animal Health and Napo Pharmaceuticals Vote to Approve Merger
Merger Terms Include Funding for Combined Company and Other Aspects of the Merger Disclosed in the Proxy/Prospectus Jaguar to Host Conference Call Friday, July 28th at 8:30 a.m. Eastern Time SAN FRANCISCO --(BUSINESS WIRE)--Jul. 27, 2017-- Jaguar Animal Health, Inc.
Toggle Summary New Data Shows Dramatic Reduction in Chronic Diarrhea Episodes with Crofelemer (Mytesi) Treatment
Results Reported at 9th International AIDS Society (IAS) Conference on HIV Science in Paris, France Over 7 Million Patients with HIV Worldwide May Benefit from the Reduction in Diarrhea Achieved with Long-Term Mytesi Therapy SAN FRANCISCO --(BUSINESS WIRE)--Jul.
Toggle Summary Jaguar Neonorm Foal Study Accepted for Publication in Veterinary Journal
SAN FRANCISCO --(BUSINESS WIRE)--Jul. 18, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, and Napo
Toggle Summary Jaguar Animal Health to Hold Special Meeting of Stockholders July 27, 2017 to Vote Upon the Consummation of its Proposed Merger with Napo Pharmaceuticals, Inc.
Terms of Proposed Merger Include Funding for Combined Company and Other Aspects of the Merger Disclosed in the Proxy/Prospectus Jaguar to Host Conference Call Friday, July 28th at 8:30 a.m. Eastern Time SAN FRANCISCO --(BUSINESS WIRE)--Jul. 6, 2017-- As previously announced, Jaguar Animal Health,
Toggle Summary Napo Pharmaceuticals to Present New Crofelemer (Mytesi) Data at International Aids Society Conference on HIV Science
Presentation will cover new data on the long-term efficacy of crofelemer (Mytesi®) based on a supplemental analysis of the ADVENT trial SAN FRANCISCO --(BUSINESS WIRE)--Jun. 27, 2017-- Napo Pharmaceuticals, Inc. , a human health company developing and commercializing novel gastrointestinal
Toggle Summary Jaguar Animal Health’s Neonorm Calf Obtains OMRI Listing and Can Now be Used in Production of Certified Organic Dairy and Beef Cattle
SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that the Organic
Toggle Summary Jaguar Animal Health Launches Commercial Website for Neonorm Foal & Neonorm Calf
Neonorm.com allows online ordering and features in-depth product information for dairy and beef farmers, foal owners and veterinarians to help drive sales SAN FRANCISCO --(BUSINESS WIRE)--Jun. 7, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on
Toggle Summary Jaguar Animal Health and Napo Pharmaceuticals Announce Filing of Two Orphan Drug Designation Applications with FDA for Mytesi for Serious Unmet Medical Needs
Napo Applications Request Orphan Drug Designation for Mytesi for Congenital Diarrheal Disorders and Diarrhea Associated with Short Bowel Syndrome Pursuit of Orphan Drug Designations Parallels Jaguar’s Focus on MUMS (Minor Use and Minor Species) Indications for Canalevia in Dogs SAN FRANCISCO
Toggle Summary Lisa Conte, CEO of Jaguar Animal Health and Napo Pharmaceuticals, to Present at the Southern California Investment Forum May 31, 2017 in Los Angeles
Management will be available for meetings during this luncheon and networking event SAN FRANCISCO --(BUSINESS WIRE)--May 25, 2017-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for
Toggle Summary Napo Pharmaceuticals’ New Mytesi Video Calls Attention to the Continuing Widespread Problem of Diarrhea in People Living With HIV/AIDS
SAN FRANCISCO --(BUSINESS WIRE)--May 24, 2017-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, which launched Mytesi ® in April, 2017, and Jaguar Animal Health,
Toggle Summary Jaguar Animal Health and Napo Pharmaceuticals Appoint Dr. Pravin Chaturvedi to Chair Scientific Advisory Board
Jaguar and Napo Comment on Potential Follow-on Indications for Mytesi, Napo’s “Pipeline Within a Product” SAN FRANCISCO --(BUSINESS WIRE)--May 10, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class
Toggle Summary Jaguar Signs Distribution Agreement for Japan for Neonorm Foal & Neonorm Calf
Jaguar Receives Extension of Nasdaq Listing SAN FRANCISCO --(BUSINESS WIRE)--Apr. 28, 2017-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals,
Toggle Summary Jaguar and Napo Issue Commercial Updates
Jaguar Kicks Off Neonorm Foal TV Campaign & Neonorm Calf Radio Campaign Sales of Neonorm Calf by Jaguar’s Distributor ANIMART Up 167% in February 2017 Compared to February 2016 Napo Launches National Sales Force for Mytesi Mytesi Study Abstract Selected for Presentation as Poster Exhibition at
Toggle Summary Jaguar Animal Health and Napo Pharmaceuticals Enter Definitive Merger Agreement
Merger Will Provide an Important Revenue Stream to Jaguar from Mytesi, an FDA Approved Napo Anti-Diarrheal Launched October 2016 Offering a First-in-Class, Novel Mechanism of Action Highly Conserved Across All Mammals SAN FRANCISCO --(BUSINESS WIRE)--Mar. 31, 2017-- Napo Pharmaceuticals, Inc.
Toggle Summary Jaguar Enters Exclusive Evaluation Period With Multinational Animal Health Pharmaceutical Firm Regarding Equilevia, Jaguar’s Drug Product Candidate for Equine Gastric Ulcer Syndrome
SAN FRANCISCO --(BUSINESS WIRE)--Mar. 28, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that
Toggle Summary Jaguar Animal Health Seeks MUMS Designation for Canalevia for Exercise-Induced Diarrhea in Dogs
SAN FRANCISCO --(BUSINESS WIRE)--Mar. 14, 2017-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that it
Toggle Summary Jaguar Animal Health to Participate in 29th Annual ROTH Conference the Week of March 13th in Orange County, California
Management will be available to schedule meetings during the conference SAN FRANCISCO --(BUSINESS WIRE)--Mar. 3, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and
Toggle Summary Napo Pharmaceuticals Signs Agreement with Alamo Pharma Services to Launch National Sales Force for Mytesi
National Sales Force Will Promote and Provide Samples of Mytesi™ to HIV Healthcare Providers SAN FRANCISCO--( BUSINESS WIRE )--Napo Pharmaceuticals, Inc., a company focused on the development and commercialization of proprietary pharmaceuticals for the global marketplace from plants traditionally
Toggle Summary Study Supporting Herd-wide Reduction in Incidence and Severity of Diarrhea With Prophylactic Use of Neonorm Calf Published in Journal of Dairy Science
Study Conducted in Association with Cornell University College of Veterinary Medicine and Demonstrates Significant Benefits Jaguar Plans to Launch the Prophylactic Formulation of Neonorm Calf this Year in Powder Form for Administration in Liquid SAN FRANCISCO --(BUSINESS WIRE)--Feb.
Toggle Summary Jaguar Animal Health Enters Binding Agreement of Terms to Merge with Napo Pharmaceuticals
Merger Will Provide an Important Revenue Stream to Jaguar from Mytesi ™ , an FDA Approved Anti-Diarrheal Launched October 2016 that Offers a First-in-Class, Novel Mechanism of Action Jaguar to Host Investor Call Thursday, February 9th at 9:00 a.m. ET SAN FRANCISCO --(BUSINESS WIRE)--Feb.
Toggle Summary Jaguar Animal Health Begins Entry Into Organic Market With Neonorm Calf
SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc. (NASDAQ: JAGX) ("Jaguar"), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that it has begun
Toggle Summary Jaguar Animal Health, Elanco Enter Global Collaboration for Development, Co-Promotion of Canalevia
Agreement provides Elanco with license rights to Jaguar’s crofelemer-based drug product candidates for treatment of diarrhea in dogs and other companion animals Jaguar Animal Health to host investor call on Tuesday, January 31st at 9:00 a.m. ET SAN FRANCISCO --(BUSINESS WIRE)--Jan.
Toggle Summary Jaguar Animal Health to Participate in Biotech Showcase 2017 Week of January 9th in San Francisco
Management will also be available to schedule meetings outside of the conference SAN FRANCISCO --(BUSINESS WIRE)--Jan. 5, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for
Toggle Summary Jaguar Animal Health Appoints Dr. Ari Azhir to Board of Directors
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 19, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that
Toggle Summary Jaguar Animal Health and Henry Schein, Inc. Sign Exclusive Distribution Agreement for Neonorm Foal
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 12, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that
Toggle Summary Jaguar Animal Health Exhibits Neonorm Foal at American Association of Equine Practitioners Annual Convention
Jaguar Also Hosted a Dinner Discussion Gathering During AAEP with Equine Veterinarian Opinion Leaders in Support of the Company’s Clinical Development Efforts SAN FRANCISCO --(BUSINESS WIRE)--Dec. 9, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on
Toggle Summary Jaguar Animal Health Announces Private Placement of Common Stock and Warrants
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 23, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that
Toggle Summary Jaguar Animal Health Issues Racing Data Summary for Horses Participating in the Company’s Recently Completed Dose Determination Study for its Drug Product Candidate for Equine Gastric Ulcer Syndrome
A Full Analysis of the Study Data with Scoring of Squamous and Glandular Ulcers is Expected to be Available in January SAN FRANCISCO --(BUSINESS WIRE)--Nov. 14, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing
Toggle Summary Jaguar Animal Health Announces Final Topline Results for Proof-of-Concept Study for Secretory Diarrhea in Dogs
Statistically Significant Final Results Confirm Interim Conclusion That Crofelemer Treatment is Superior to Placebo SAN FRANCISCO --(BUSINESS WIRE)--Oct. 18, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class
Toggle Summary Jaguar Animal Health and Napo Pharmaceuticals Announce Details for Proposed Merger
Merger Would Allow Jaguar to Recognize an Important Revenue Stream from First-in-Class, Novel Mechanism of Action of the Anti-diarrheal Mytesi SAN FRANCISCO --(BUSINESS WIRE)--Oct. 6, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and
Toggle Summary Jaguar Animal Health Signs Exclusive Distribution Agreement for Croton lechleri Botanical Extract for Pigs and Dairy Cattle in the Chinese Marketplace
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 7, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses,
Toggle Summary Jaguar Animal Health Announces Additional Topline Results from Study of Second-Generation Formulation of Neonorm Calf Conducted in Association with Cornell University College of Veterinary Medicine
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 1, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses,
Toggle Summary Jaguar Animal Health Announces Positive Preliminary Topline Results of Two Chinese-sponsored Farm Studies to Evaluate the Safety and Effectiveness of Neonorm Botanical Extract in Piglets
High resolution in treated animals versus high mortality in control piglets, 1-3 days old Jaguar has entered into negotiations for a potential exclusive distribution relationship for pigs and dairy cattle in the Chinese marketplace with the China-based business entity involved in conducting these
Toggle Summary Jaguar Animal Health Appoints Leading Oncologist and Drug Development Executive as Chief Scientific Officer
Dr. Roger Waltzman to Lead Development Teams for Jaguar’s SB-300 and Canalevia Drug Product Candidates SAN FRANCISCO --(BUSINESS WIRE)--Jun. 30, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing
Toggle Summary Jaguar Animal Health Announces Positive Topline Results of University Study of Second-Generation Formulation of Neonorm Calf and Commercialization Strategy Updates
Advances commercialization strategy for equine and companion animal drug product candidates SAN FRANCISCO --(BUSINESS WIRE)--Jun. 17, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class
Toggle Summary Jaguar Animal Health Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
SAN FRANCISCO --(BUSINESS WIRE)--Jun. 9, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses,
Toggle Summary Jaguar Animal Health Initiates Dose Determination Study with the Target Commercial Paste Formulation of SB-300, the Company’s Drug Product Candidate for Treatment of Equine Gastric Ulcer Syndrome
SAN FRANCISCO --(BUSINESS WIRE)--May 4, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses,
Toggle Summary SB-300, Jaguar’s Drug Product Candidate for the Treatment of Gastric Ulcers, Enables Continued Therapy in Performance Horses in Accordance with Standard Testing Guidelines
Results of Initial Study Show that Jaguar’s Equine Product Candidate for Treatment of Gastric Ulcers May Offer Horse Owners an Additional Advantage in the Competition Horse World, where Requirements Exist for Animals to Compete Free from the Effect of Any Drugs SAN FRANCISCO --(BUSINESS WIRE)--Apr.
Toggle Summary Jaguar Animal Health Obtains Protocol Concurrence From FDA for Canalevia Drug Product Candidate for Treatment of Acute Diarrhea in Dogs
SAN FRANCISCO --(BUSINESS WIRE)--Apr. 13, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses,
Toggle Summary Jaguar Animal Health Appoints John Micek III to Board of Directors
SAN FRANCISCO --(BUSINESS WIRE)--Apr. 6, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses,
Toggle Summary Jaguar Animal Health Appoints Dr. Philippe Brianceau as Chief Veterinary Officer
SAN FRANCISCO --(BUSINESS WIRE)--Feb. 22, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced today the
Toggle Summary Jaguar’s SB-300 Drug Product Candidate in Development
Advantages as an Alternative Approach to the Management of Gastrointestinal Ulcers in Horses SAN FRANCISCO --(BUSINESS WIRE)--Feb. 16, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class
Toggle Summary Jaguar Animal Health, Inc. Announces Closing of Public Offering; Secures Funding Through Anticipated Launch of First Prescription Drug Product Candidate
Progress on Rx Product Pipeline SAN FRANCISCO --(BUSINESS WIRE)--Feb. 9, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, today announced the
Toggle Summary Jaguar Animal Health, Inc. Prices 2,000,000 Common Share Offering
SAN FRANCISCO , Feb. 3, 2016 /PRNewswire/ --   Jaguar Animal Health, Inc. (Nasdaq: JAGX) , an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced today the pricing of an
Toggle Summary Jaguar Animal Health Reports Topline Findings for its Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in Horses
SAN FRANCISCO --(BUSINESS WIRE)--Jan. 28, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced
Toggle Summary Jaguar Animal Health Initiates University Study to Further Investigate Possible Prophylactic and Prebiotic Benefits of a Second-Generation Formulation of Neonorm in Dairy Calves
SAN FRANCISCO --(BUSINESS WIRE)--Jan. 7, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary Jaguar Animal Health Initiates Pivotal Field Study to Evaluate Safety and Effectiveness of Canalevia Drug Product Candidate for Treatment of Acute Diarrhea in Dogs
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 22, 2015-- Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced today that it has initiated a pivotal
Toggle Summary Jaguar Animal Health Announces Positive Results in University Pilot Safety Study of Crofelemer in Horses
Study is First Step in Jaguar’s Development Program for a Crofelemer Drug Product Candidate for Treatment of Diarrhea Associated with Acute Colitis in Horses SAN FRANCISCO --(BUSINESS WIRE)--Dec. 21, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health
Toggle Summary Jaguar Animal Health Announces Positive Results of Investigator-Initiated Follow-up Neonorm Study in Foals
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 18, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced positive
Toggle Summary Jaguar Animal Health Appoints Karen Wright as Chief Financial Officer
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 16, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced
Toggle Summary Jaguar Animal Health Completes Enrollment for Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in Horses
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 15, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced
Toggle Summary Jaguar Animal Health Initiates University Pilot Safety Study to Evaluate Use of Crofelemer for the Treatment of Diarrhea Associated with Acute Colitis in Horses
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 3, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary Jaguar Animal Health to Present at the 2015 LD Micro Conference on December 3rd in Los Angeles
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 23, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that Steven King ,
Toggle Summary Jaguar Animal Health Announces Positive Results from Proof-of-Concept Study of Neonorm in Foals
Product Launching at the American Association of Equine Practitioners Annual Convention December 5-9 th SAN FRANCISCO --(BUSINESS WIRE)--Nov. 16, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing
Toggle Summary Jaguar Animal Health Initiates Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in Horses
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 5, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary University Study Supports Benefit of Jaguar Animal Health’s Neonorm Calf on Intestinal Microbiome in Pre-weaned Dairy Calves
SAN FRANCISCO --(BUSINESS WIRE)--Oct. 27, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that a recently
Toggle Summary U.S. Patent and Trademark Office Issues Notices of Allowance in Two Pending NP-500 Patent Applications Licensed Exclusively by Jaguar Animal Health for Veterinary Use
NP-500 is the Active Pharmaceutical Ingredient in Jaguar’s Drug Product Candidates to Treat Diseases Related to Insulin-resistance in Dogs, Horses & Cats SAN FRANCISCO --(BUSINESS WIRE)--Oct. 26, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health
Toggle Summary Jaguar Animal Health to Host Analyst and Investor Day on November 16, 2015 in New York City
SAN FRANCISCO --(BUSINESS WIRE)--Oct. 26, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it will host
Toggle Summary Jaguar Animal Health Signs Crofelemer Formulation Development and Manufacturing Contract with Patheon
Contract Secured in Preparation for Pivotal Trial & Expected Launch of Jaguar’s Prescription Drug Candidate, Canalevia, for Acute Diarrhea in Dogs Jaguar to Leverage Patheon’s Experience Manufacturing FDA-approved, Human-specific Formulation of Crofelemer SAN FRANCISCO --(BUSINESS WIRE)--Oct.
Toggle Summary Jaguar Animal Health Completes Second Neonorm Field Study Indicating Beneficial Effect of Product on Pre-Wean Weight Gain & Normalization of Stool Formation in Dairy Calves Beyond Current Standard of Care
SAN FRANCISCO --(BUSINESS WIRE)--Oct. 7, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today the results of a
Toggle Summary Jaguar Animal Health to Present at the Aegis Capital 2015 Growth Conference
SAN FRANCISCO --(BUSINESS WIRE)--Oct. 2, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that Lisa Conte ,
Toggle Summary Jaguar Animal Health Signs Crofelemer Manufacturing & Supply Agreement with Glenmark Pharmaceuticals Ltd.
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 28, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary Jaguar Animal Health Initiates Proof-of-Concept Study to Evaluate Safety, Tolerability & Efficacy of Neonorm in Foals
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 25, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary Study Evaluating Effect of Jaguar Animal Health’s Neonorm on Diarrhea in Newborn Dairy Calves Published in Journal of Dairy Science
Study Conducted at Cornell University College of Veterinary Medicine SAN FRANCISCO --(BUSINESS WIRE)--Sep. 2, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for
Toggle Summary Jaguar Animal Health to Attend the 2015 KC Animal Health Investment Forum
SAN FRANCISCO --(BUSINESS WIRE)--Aug. 25, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that Lisa Conte ,
Toggle Summary Jaguar Animal Health Secures Debt Financing
SAN FRANCISCO --(BUSINESS WIRE)--Aug. 19, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary Jaguar Animal Health Submits All Required Major Technical Sections of New Animal Drug Application for Canalevia
Company Prepares for New Prescription Drug Launch in First Half of 2016 for Dogs Suffering from Chemotherapy-Induced Diarrhea SAN FRANCISCO --(BUSINESS WIRE)--Aug. 19, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and
Toggle Summary KCSA Strategic Communications to Lead Investor Relations Program for Jaguar Animal Health
NEW YORK , July 16, 2015 /PRNewswire/ -- KCSA Strategic Communications, a prominent New York -based communications firm, announced today that it has been retained by Jaguar Animal Health, Inc. (NASDAQ: JAGX ) ("Jaguar" or the "Company"), an animal health company focused on developing and
Toggle Summary Jaguar Animal Health Appoints Dr. Victoria Lewis as Chief of Clinical Development
SAN FRANCISCO --(BUSINESS WIRE)--Jul. 7, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary Jaguar Completes Study in Dogs with Chemotherapy-Induced Diarrhea with Commercial Formulation of Canalevia
Jaguar Targeting First Prescription Product Launch in Early 2016 SAN FRANCISCO --(BUSINESS WIRE)--Jul. 1, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for
Toggle Summary Jaguar Animal Health, Inc. Added to Russell Microcap Index
SAN FRANCISCO --(BUSINESS WIRE)--Jun. 30, 2015-- Jaguar Animal Health, Inc. (Nasdaq:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it was added
Toggle Summary Jaguar Animal Health Field Study Confirms Beneficial Effect of Neonorm on Average Daily Weight in Calves
Results Support Study to Investigate Potential Prebiotic Effect on Calf Gut Microbiome SAN FRANCISCO --(BUSINESS WIRE)--Jun. 9, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion
Toggle Summary Jaguar Animal Health Appoints Industry Expert Folkert Kamphuis to Board of Directors
SAN FRANCISCO --(BUSINESS WIRE)--Jun. 3, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has named Folkert Kamphuis to its board
Toggle Summary Jaguar Animal Health, Inc. Announces Pricing of Initial Public Offering
SAN FRANCISCO --(BUSINESS WIRE)--May 13, 2015-- Jaguar Animal Health, Inc. (Nasdaq: JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today the pricing of its initial public offering of
Toggle Summary Jaguar Animal Health Files Two Provisional Patent Applications, Deepening its Pipeline of Proprietary Gastrointestinal Products for Animals
One Application Covers the Combined Use of Croton lechleri-derived Products and Rifaximin to Address Diarrhea Symptoms The Second is for the Prebiotic Benefit of Crofelemer and Croton lechleri-derived Products in Dairy Calves and Other Animals San Francisco, CA (March 4, 2015): Jaguar Animal
Toggle Summary Jaguar Animal Health Signs Agreement with Latin America’s Largest Veterinary Biotechnology Company
San Francisco, CA (February 26, 2015): Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has entered into a supply and distribution
Toggle Summary Jaguar Animal Health Announces Outcome of Canine Proof-of-Concept Study for Canalevia
Statistically Significant Results Support the Conclusion that Canalevia Treatment is Superior to Placebo 91.0% of Treated Dogs Achieved a Formed Stool During the Study Versus 50.0% of Placebo-treated Animals San Francisco, CA (February 19, 2015): Jaguar Animal Health, Inc.
Toggle Summary Jaguar Animal Health Files Ninth Investigational New Animal Drug Application
Drug Candidate Addresses Gastric, Intestinal and Colonic Ulcers in Horses and Foals San Francisco, CA (February 10, 2015): Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal and other proprietary health products
Toggle Summary Jaguar Animal Health Signs Distribution Agreement with Vedco and Kicks off National Neonorm Calf Marketing Campaign
Jaguar Exhibiting at World Ag Expo & Western Veterinary Conference this Month San Francisco, CA (February 5, 2015): Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production
Toggle Summary Jaguar Animal Health Initiates Filing of Its First New Animal Drug Application with FDA
Canalevia™ is a New Prescription Drug Candidate for Treatment of Dogs Undergoing Chemotherapy San Francisco, CA (December 22, 2014): Jaguar Animal Health, Inc., an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production
Toggle Summary Jaguar Animal Health Completes Equine Study for Safety & Palatability of Neonorm™ Foal Gastrointestinal Product
San Francisco, CA (December 4, 2014): Jaguar Animal Health, Inc. (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has completed a study designed to
Toggle Summary Jaguar Animal Health Appoints Former Merial Executive to Head Regulatory Affairs
San Francisco, CA (November 21, 2014): Jaguar Animal Health, Inc. (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has appointed Tim Dotson, a
Toggle Summary Jaguar Animal Health, Inc. Launches First Product, Neonorm™ Calf, at World Dairy Expo
ANIMART Named First Commercial Partner September 29, 2014 08:30 AM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )--Today, Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and
Toggle Summary Jaguar Animal Health, Inc. Files Eighth Investigational New Animal Drug Application
SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal and other proprietary health products for companion and production animals, announced today that it has submitted its eighth
Toggle Summary Jaguar Animal Health Names VP, Commercial Operations
09:38 AM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc., (“Jaguar” or the “Company”) an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, today named Ian Parker, a
Toggle Summary Jaguar Files INADAs for Diarrhea in Companion Animals and Horses
March 03, 2014 03:15 PM Eastern Standard Time SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc. (“Jaguar”) announced today that it has submitted three Investigational New Animal Drug Applications (“INADA”) with the Center for Veterinary Medicine of the US Food and Drug Administration
Toggle Summary Jaguar Announces Initial Close of Series A Round
SAN FRANCISCO , Feb. 5, 2014 /PRNewswire/ -- Jaguar Animal Health, Inc. ("Jaguar") announced an initial $2 million closing of its Series A round of financing.   BioVeda China Fund ("BVCF"), a private equity and growth capital investor based in China, funded the initial closing and
Toggle Summary Drug Application For Chemo-induced Diarrhea In Dogs Moving Forward
SAN FRANCISCO Jan. 14, 2014 /PRNewswire/ -- An investigational new animal drug application (INADA) number has been received by Napo Pharmaceuticals, Inc. for its lead animal drug candidate, SP-303, which is isolated and purified from Croton lechleri, a medicinal plant sustainably harvested from the